PharmAsia News Notable Notes: Will Rising Rupee Continue To Hold Back Retooled Indian Pharma Firms?

NEW DELHI - A confluence of new revenues from contract research and manufacturing services, in-license deals from multinational drug firms, vigorous efforts to discover new drugs, a slew of successful patent challenges and an upbeat outlook for generic drug demand, make leading Indian pharma companies attractive investments in a downbeat global economy, according to a 55-page report by IDFC-SSKI, the investment banking subsidiary of Mumbai-based Infrastructure Development Finance Company